HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List for ELUNATE® and ORPATHYS®
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 15, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that following the contract renewal with the China National Healthcare Security Administration (“NHSA”), the updated National Reimbursement Drug List (“NRDL”) effective on January 1, 2027 will continue to include ELUNATE ® , ORPATHYS ® and SULANDA ® . This update reflects expanded coverage for new indications, renewed agreements for existing indications, as well as continued inclusion under current multi-year agreements.